GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

The Centers for Disease Control and Prevention is urging some people to get additional doses of the COVID-19 vaccine for ...

Shawn Johnson East is an Olympic and Dancing with the Stars champion who earned serious “cool mom” street cred in 2023 when ...

The season for respiratory illnesses is quickly approaching. Some medical professionals in Alabama are pushing this ...

The CDC seems to be taking an “if it ain’t broke” approach to its annual flu vaccine push. | The CDC seems to be taking an ...

The CDC's vaccine policy advisors haven't budged on new RSV guidance, remaining unconvinced that younger adults at higher ...

The Mississippi State Department of Health encourages everyone to get appropriate updated vaccinations to avoid severe ...

Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...

FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.

GSK (GSK) reported its RSV vaccine Arexvy elicited a robust immune response in people aged 18 to 49 years who were at ...

The number of people infected with bird flu in the U.S. has risen to at least 31, federal health officials said Thursday, but ...